AR032316A1 - Uso de una composicion farmaceutica para la fabricacion de medicamentos y una composicion farmaceutica - Google Patents
Uso de una composicion farmaceutica para la fabricacion de medicamentos y una composicion farmaceuticaInfo
- Publication number
- AR032316A1 AR032316A1 ARP010101698A ARP010101698A AR032316A1 AR 032316 A1 AR032316 A1 AR 032316A1 AR P010101698 A ARP010101698 A AR P010101698A AR P010101698 A ARP010101698 A AR P010101698A AR 032316 A1 AR032316 A1 AR 032316A1
- Authority
- AR
- Argentina
- Prior art keywords
- hypertension
- pharmaceutical composition
- renal failure
- pharmaceutically acceptable
- manufacture
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 4
- 239000003814 drug Substances 0.000 title abstract 3
- 238000004519 manufacturing process Methods 0.000 title abstract 3
- 206010020772 Hypertension Diseases 0.000 abstract 6
- 208000001647 Renal Insufficiency Diseases 0.000 abstract 2
- 239000002333 angiotensin II receptor antagonist Substances 0.000 abstract 2
- 239000000400 angiotensin II type 1 receptor blocker Substances 0.000 abstract 2
- 208000020832 chronic kidney disease Diseases 0.000 abstract 2
- 208000022831 chronic renal failure syndrome Diseases 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 2
- 201000006370 kidney failure Diseases 0.000 abstract 2
- 208000037803 restenosis Diseases 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 2
- 229940123338 Aldosterone synthase inhibitor Drugs 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 206010007559 Cardiac failure congestive Diseases 0.000 abstract 1
- 102000008186 Collagen Human genes 0.000 abstract 1
- 108010035532 Collagen Proteins 0.000 abstract 1
- 206010048554 Endothelial dysfunction Diseases 0.000 abstract 1
- 206010016654 Fibrosis Diseases 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 206010022489 Insulin Resistance Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 238000002399 angioplasty Methods 0.000 abstract 1
- 230000001028 anti-proliverative effect Effects 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 229920001436 collagen Polymers 0.000 abstract 1
- 208000029078 coronary artery disease Diseases 0.000 abstract 1
- 210000004351 coronary vessel Anatomy 0.000 abstract 1
- 239000002934 diuretic Substances 0.000 abstract 1
- 230000001882 diuretic effect Effects 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 230000008694 endothelial dysfunction Effects 0.000 abstract 1
- 230000004761 fibrosis Effects 0.000 abstract 1
- 208000003532 hypothyroidism Diseases 0.000 abstract 1
- 230000002989 hypothyroidism Effects 0.000 abstract 1
- 208000017169 kidney disease Diseases 0.000 abstract 1
- 208000010125 myocardial infarction Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 238000007634 remodeling Methods 0.000 abstract 1
- 238000001356 surgical procedure Methods 0.000 abstract 1
- 230000004083 survival effect Effects 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
El uso de una composicion farmacéutica que comprende: i) un inhibidor de aldosterona-sintasa o una sal farmacéuticamente aceptable del mismo, solo o en combinacion con: (ii) un antagonista del receptor AT1, o un antagonista del receptor AT1 combinado con un diurético, o en cada caso, una sal farmacéuticamente aceptable de los mismos, y (iii) un vehículo farmacéuticamente aceptable; que es para la fabricacion de un medicamento para la prevencion, demora de progreso, o tratamiento de una enfermedad o condicion seleccionada a partir del grupo que consiste en: (a) hipertension, insuficiencia cardíaca congestiva, insuficiencia renal, especialmente insuficiencia renal cronica, restenosis después de angioplastía transluminal percutánea, y restenosis después de cirugía de derivacion arterial coronaria; (b) ateroesclerosis, resistencia a la insulina y síndrome X, diabetes mellitus tipo 2, obesidad, nefropatía, insuficiencia renal, por ejemplo insuficiencia renal cronica, hipotiroidismo, sobrevivencia posterior a infarto al miocardio (MI), enfermedades cardíacas coronarias, hipertension en la ancianidad, hipertension dislepidémica familiar, incremento de formacion de colágeno, fibrosis, y remodelacion enseguida de hipertension (efecto antiproliferativo de la combinacion), todas estas enfermedades o condiciones asociadas con o sin hipertension; (c) disfuncion endotelial con o sin hipertension; para la fabricacion de medicamentos y una composicion farmacéutica.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19674200P | 2000-04-12 | 2000-04-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR032316A1 true AR032316A1 (es) | 2003-11-05 |
Family
ID=22726655
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP010101698A AR032316A1 (es) | 2000-04-12 | 2001-04-10 | Uso de una composicion farmaceutica para la fabricacion de medicamentos y una composicion farmaceutica |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP1282410A2 (es) |
| JP (1) | JP2003530343A (es) |
| KR (1) | KR20020089437A (es) |
| CN (1) | CN1422152A (es) |
| AR (1) | AR032316A1 (es) |
| AU (2) | AU2001273938B2 (es) |
| BR (1) | BR0110079A (es) |
| CA (1) | CA2405895A1 (es) |
| HU (1) | HUP0301335A3 (es) |
| IL (1) | IL152081A0 (es) |
| MX (1) | MXPA02010091A (es) |
| NO (1) | NO20024920L (es) |
| NZ (1) | NZ521855A (es) |
| PE (1) | PE20020082A1 (es) |
| PL (1) | PL358459A1 (es) |
| RU (1) | RU2002129569A (es) |
| SK (1) | SK14612002A3 (es) |
| WO (1) | WO2001076574A2 (es) |
| ZA (1) | ZA200208204B (es) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004518611A (ja) * | 2000-07-27 | 2004-06-24 | ファルマシア・コーポレーション | 炎症関連障害を予防するか又は治療するためのアルドステロン遮断薬療法 |
| US6777443B2 (en) | 2001-05-15 | 2004-08-17 | Novartis Ag | Dipeptide derivatives |
| US7232828B2 (en) * | 2002-08-10 | 2007-06-19 | Bethesda Pharmaceuticals, Inc. | PPAR Ligands that do not cause fluid retention, edema or congestive heart failure |
| AU2003292775A1 (en) * | 2002-12-27 | 2004-07-29 | Takeda Pharmaceutical Company Limited | Body weight gain inhibitor |
| SE0300988D0 (sv) * | 2003-04-03 | 2003-04-03 | Astrazeneca Ab | New use |
| WO2005099695A1 (en) * | 2004-04-19 | 2005-10-27 | Novartis Ag | Drug delivery systems for the prevention and treatment of vascular diseases |
| ITTO20040760A1 (it) * | 2004-11-03 | 2005-02-03 | Uni Degli Studi Del Piemonte | Uso di un corticosteroide in associazione ad altri principi attivi per il trattamento della stenosi vascolare e la prevenzione della restenosi vascolare |
| WO2006066961A1 (en) * | 2004-12-24 | 2006-06-29 | Krka, D.D., Novo Mesto | Solid pharmaceutical composition comprising valsartan |
| EP1674080A1 (en) * | 2004-12-24 | 2006-06-28 | KRKA, D.D., Novo Mesto | Solid pharmaceutical composition comprising valsartan |
| EP1853261B1 (de) | 2005-03-03 | 2017-01-11 | Universität des Saarlandes | Selektive hemmstoffe humaner corticoidsynthasen |
| TW200716636A (en) | 2005-05-31 | 2007-05-01 | Speedel Experimenta Ag | Heterocyclic spiro-compounds |
| GT200600381A (es) | 2005-08-25 | 2007-03-28 | Compuestos organicos | |
| EP1842543A1 (en) | 2006-04-05 | 2007-10-10 | Speedel Pharma AG | Pharmaceutical composition coprising an aldosterone synthase inhibitor and a mineralcorticoid receptor antagonist |
| TW200808812A (en) * | 2006-04-12 | 2008-02-16 | Speedel Experimenta Ag | Imidazo compounds |
| TW200808813A (en) * | 2006-04-12 | 2008-02-16 | Speedel Experimenta Ag | Imidazo compounds |
| EP2095819A1 (en) | 2008-02-28 | 2009-09-02 | Maastricht University | N-benzyl imidazole derivatives and their use as aldosterone synthase inhibitors |
| JP5420761B2 (ja) | 2009-05-28 | 2014-02-19 | ノバルティス アーゲー | ネプリリシン阻害剤としての置換アミノプロピオン酸誘導体 |
| MX2011012627A (es) | 2009-05-28 | 2011-12-14 | Novartis Ag | Derivados aminobutiricos sustituidos como inhibidores de nepralisina. |
| JO2967B1 (en) | 2009-11-20 | 2016-03-15 | نوفارتس ايه جي | Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors |
| US8673974B2 (en) | 2010-11-16 | 2014-03-18 | Novartis Ag | Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors |
| US8877815B2 (en) | 2010-11-16 | 2014-11-04 | Novartis Ag | Substituted carbamoylcycloalkyl acetic acid derivatives as NEP |
| ES2683350T3 (es) | 2011-07-08 | 2018-09-26 | Novartis Ag | Método para tratar la aterosclerosis en sujetos con alto nivel de triglicéridos |
| UY35144A (es) | 2012-11-20 | 2014-06-30 | Novartis Ag | Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca |
| PE20151666A1 (es) | 2013-02-14 | 2015-11-19 | Novartis Ag | Derivados sustituidos del acido bisfenil butanoico fosfonico como inhibidores de la nep |
| TW201536814A (zh) | 2013-07-25 | 2015-10-01 | Novartis Ag | 用於治療心臟衰竭之合成環狀多肽 |
| PE20160991A1 (es) | 2013-07-25 | 2016-10-15 | Novartis Ag | Bioconjugados de polipeptidos de apelina sintetica |
| CA2972871A1 (en) | 2015-01-23 | 2016-07-28 | Novartis Ag | Synthetic apelin fatty acid conjugates with improved half-life |
| JOP20190086A1 (ar) | 2016-10-21 | 2019-04-18 | Novartis Ag | مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب |
| IL301471B2 (en) * | 2016-10-27 | 2025-02-01 | Damian Pharma Ag | Aldosterone synthase inhibitor |
| UY38072A (es) | 2018-02-07 | 2019-10-01 | Novartis Ag | Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos |
| SG11202010906XA (en) * | 2018-05-03 | 2020-12-30 | Damian Pharma Ag | R-fadrozole for use in the treatment of aldostonerism |
| EP3887363A1 (en) | 2018-11-27 | 2021-10-06 | Novartis AG | Cyclic pentamer compounds as proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors for the treatment of metabolic disorder |
| UY38485A (es) | 2018-11-27 | 2020-06-30 | Novartis Ag | Compuestos tetrámeros cíclicos como inhibidores de proproteína convertasa subtilisina/kexina tipo 9 (pcsk9), método de tratamiento, uso y su preparación |
| CN113166204B (zh) | 2018-11-27 | 2025-01-28 | 诺华股份有限公司 | 作为治疗代谢障碍的蛋白质原转换酶枯草杆菌蛋白酶/kexin 9型（PCSK9）抑制剂的环状肽 |
| WO2023084449A1 (en) | 2021-11-12 | 2023-05-19 | Novartis Ag | Diaminocyclopentylpyridine derivatives for the treatment of a disease or disorder |
| AR127698A1 (es) | 2021-11-23 | 2024-02-21 | Novartis Ag | Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno |
| WO2024241229A1 (en) | 2023-05-24 | 2024-11-28 | Novartis Ag | Naphthyridinone derivatives for the treatment of a disease or disorder |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5252565A (en) * | 1990-04-02 | 1993-10-12 | Merrell Dow Pharmaceuticals Inc. | Haloethyl-substituted steroid enzyme inhibitors |
| JPH0971586A (ja) * | 1995-09-07 | 1997-03-18 | Yamanouchi Pharmaceut Co Ltd | 新規な二環性縮合イミダゾール誘導体 |
| EP0930876B2 (en) * | 1996-07-22 | 2010-07-07 | Renovo Limited | Use of compounds that promote oestrogenic activity for acclerating the healing of skin wounds |
| US5906987A (en) * | 1997-03-10 | 1999-05-25 | Schering Aktiengesellschaft And Board Of Regents | Treatment of male climacteric disorders with nitric oxide synthase substrates and/or donors, in combination with androgens and/or aromatase inhibitors |
| FR2766821A1 (fr) * | 1997-07-29 | 1999-02-05 | Sanofi Sa | Derives de 1,3-oxazolinyl-biphenyle, leur procede de preparation et leur utilisation comme intermediaires de synthese |
| US5972921A (en) * | 1997-12-12 | 1999-10-26 | Hormos Medical Oy Ltd. | Use of an aromatase inhibitor in the treatment of decreased androgen to estrogen ratio and detrusor urethral sphincter dyssynergia in men |
| ZA991922B (en) * | 1998-03-11 | 1999-09-13 | Smithkline Beecham Corp | Novel compositions of eprosartan. |
| PT1096932E (pt) * | 1998-07-10 | 2007-09-21 | Novartis Pharma Ag | ''combinação anti-hipertensiva de valsartan e bloqueadores do canal de cálcio'' |
-
2001
- 2001-04-10 NZ NZ521855A patent/NZ521855A/en unknown
- 2001-04-10 RU RU2002129569/15A patent/RU2002129569A/ru not_active Application Discontinuation
- 2001-04-10 AU AU2001273938A patent/AU2001273938B2/en not_active Ceased
- 2001-04-10 AU AU7393801A patent/AU7393801A/xx active Pending
- 2001-04-10 WO PCT/EP2001/004116 patent/WO2001076574A2/en not_active Ceased
- 2001-04-10 EP EP01940317A patent/EP1282410A2/en not_active Withdrawn
- 2001-04-10 JP JP2001574092A patent/JP2003530343A/ja active Pending
- 2001-04-10 MX MXPA02010091A patent/MXPA02010091A/es not_active Application Discontinuation
- 2001-04-10 HU HU0301335A patent/HUP0301335A3/hu unknown
- 2001-04-10 AR ARP010101698A patent/AR032316A1/es not_active Application Discontinuation
- 2001-04-10 BR BR0110079-3A patent/BR0110079A/pt not_active IP Right Cessation
- 2001-04-10 PE PE2001000328A patent/PE20020082A1/es not_active Application Discontinuation
- 2001-04-10 PL PL01358459A patent/PL358459A1/xx not_active Application Discontinuation
- 2001-04-10 KR KR1020027013486A patent/KR20020089437A/ko not_active Ceased
- 2001-04-10 IL IL15208101A patent/IL152081A0/xx unknown
- 2001-04-10 CA CA002405895A patent/CA2405895A1/en not_active Abandoned
- 2001-04-10 CN CN01807917A patent/CN1422152A/zh active Pending
- 2001-04-10 SK SK1461-2002A patent/SK14612002A3/sk unknown
-
2002
- 2002-10-11 ZA ZA200208204A patent/ZA200208204B/en unknown
- 2002-10-11 NO NO20024920A patent/NO20024920L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CN1422152A (zh) | 2003-06-04 |
| AU2001273938B2 (en) | 2005-03-03 |
| IL152081A0 (en) | 2003-05-29 |
| CA2405895A1 (en) | 2001-10-18 |
| KR20020089437A (ko) | 2002-11-29 |
| WO2001076574A2 (en) | 2001-10-18 |
| HUP0301335A2 (hu) | 2003-08-28 |
| NZ521855A (en) | 2004-10-29 |
| NO20024920L (no) | 2002-11-27 |
| EP1282410A2 (en) | 2003-02-12 |
| AU7393801A (en) | 2001-10-23 |
| HUP0301335A3 (en) | 2006-02-28 |
| RU2002129569A (ru) | 2004-03-27 |
| SK14612002A3 (sk) | 2003-05-02 |
| MXPA02010091A (es) | 2003-02-12 |
| WO2001076574A3 (en) | 2002-04-25 |
| ZA200208204B (en) | 2003-10-14 |
| BR0110079A (pt) | 2002-12-31 |
| JP2003530343A (ja) | 2003-10-14 |
| PE20020082A1 (es) | 2002-02-21 |
| NO20024920D0 (no) | 2002-10-11 |
| PL358459A1 (en) | 2004-08-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR032316A1 (es) | Uso de una composicion farmaceutica para la fabricacion de medicamentos y una composicion farmaceutica | |
| AR032152A1 (es) | Uso de una combinacion de compuestos terapeuticos organicos para la fabricacion de un medicamento, un agente terapeutico, y una composicion farmaceutica | |
| Gorog et al. | Antithrombotic therapy in patients with acute coronary syndrome complicated by cardiogenic shock or out-of-hospital cardiac arrest: a joint position paper from the European Society of Cardiology (ESC) Working Group on Thrombosis, in association with the Acute Cardiovascular Care Association (ACCA) and European Association of Percutaneous Cardiovascular Interventions (EAPCI) | |
| Santos et al. | Pharmacological effects of AVE 0991, a nonpeptide angiotensin‐(1–7) receptor agonist | |
| JP2021095409A (ja) | 心臓保護及び腎臓保護の抗糖尿病治療におけるリナグリプチンの使用 | |
| CO6251256A2 (es) | Sales del inhibidor de janus cinasa (r)-3-(4-(7h-pirrolo[2,3-d]pirimidin-4il)1h-pirazol-1-il)-3-ciclopentilpropanitrilo | |
| WO1995014384A1 (en) | Inhibition of smooth muscle migration and proliferation with hydroxy carbazole compounds | |
| UY27965A1 (es) | Derivados heterocíclicos | |
| TW200635897A (en) | Piperidine derivatives and their use as anti-inflammatory agents | |
| RU2006132668A (ru) | Синергетические комбинации, которые содержат ингибитор ренина, предназначенные для лечения сердечно-сосудистых заболеваний | |
| JP2005532330A5 (es) | ||
| WO2003105800A3 (de) | Filmförmige mucoadhäsive darreichungsformen zur verabreichung von cannabis-wirkstoffen | |
| CR7074A (es) | Derivados de mercaptoacetylamida y proceso para su preparacion y uso | |
| AR048588A1 (es) | Uso de inhibidores de la fosfodiesterasa de tipo iii (pde iii) para la reduccion del tamano del corazon en mamiferos que padecen insuficiencia cardiaca | |
| RU2006136091A (ru) | Применение органических соединений | |
| AR052221A1 (es) | Metodo para el tratamiento de la enfermedad poliquistosis renal | |
| JP2009504737A (ja) | 脈管疾患の治療又は予防のためのｐａｒ−１／ｐａｒ−４阻害剤の使用 | |
| ATE442158T1 (de) | Oral verabreichte pharmazeutische zusammensetzungen mit einem abgabemittel in mikronisierter form | |
| BR0115516A (pt) | Composição farmacêutica, e, método para prevenir ou tratar hipertensão | |
| JP2025027020A (ja) | 患者において血清リン酸塩を低下させるための組み合わせ | |
| WO2007054514A3 (en) | Use of pde iii inhibitors or calcium sensitizers for the treatment of asymptomatic (occult) heart failure | |
| AR030379A1 (es) | Combinaciones | |
| AR029637A1 (es) | Compuestos de guanidina, antagonistas de los receptores de la il-8, una composicion farmaceutica que los contiene y el uso de los mismos para la manufactura de un medicamento | |
| Ellahham et al. | Bosentan and the endothelin system in congestive heart failure | |
| ES2247060T3 (es) | Producto que comprende un inhibidor de la transduccion de las señales de las proteinas g heterotrimericas en asociacion con un agente antihipertensor para una utilizacion terapeutica en el tratamiento de la hipertension arterial. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |